A report published yesterday provides recommendations for combating the “significant inequalities” affecting access to quality cancer care in Europe.
A report published yesterday provides recommendations for combating the “significant inequalities” affecting access to quality cancer care in Europe.
Cancer is still the second leading cause of death in the European Union, responsible for around 1.3 million of all 5 million deaths per year.
Based on a review of colorectal, lung and prostate cancer care in France, Germany, Poland and Sweden, the “Access to high-quality oncology care across Europe” report, commissioned by Janssen and based on research by the Swedish Institute for Health Economics (IHE), offers six initial policy recommendations. It states a need for:
1. cost-effective allocation of provision and spending;
2. improved funding and resourcing;
3. incentivization of innovative research, including the design of reimbursement systems, reward of innovations in cancer care, and the development of new payment schemes;
4. better integrated and organized cancer care system;
5. collation of data on resource use and outcomes to monitor standards and regional differences; and
6. more recognition of the quality of life as an outcome measure for the individual and society.
The report’s co-author, Bengt Jonsson, of the Stockholm School of Economics, highlighted that “France has the quickest and most extensive uptake of new cancer drugs followed by Germany, while here in Sweden we are falling behind Germany and France. Poland meanwhile, falls significantly behind all three.”
For more information: http://www.prnewswire.co.uk/news-releases/253705791.html.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.